Please enable Javascript
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Study Identifies Features that Predict Follicular Lymphoma Early Relapse
Patrick Daly
Follicular Lymphoma
|
April 9, 2024
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
Read More
FDA Declines BLA for Odronextamab for Non-Hodgkin Lymphoma
Melissa Badamo
Aggressive B-Cell Lymphoma
|
March 25, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Read More
FDA Approves Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
March 7, 2024
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Read More
Axi-Cel Leads to ‘Continued Durable Responses’ in Patients With Indolent B-Cell Lymphoma
Cecilia Brown
Indolent B-Cell Lymphoma
|
March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Read More
External Comparator Analysis Supports Long-term Value of Axi-Cel in Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
March 7, 2024
Axi-cel yielded improved long-term outcomes versus conventional treatments in extended follow-up of the ZUMA-5 trial.
Read More
Liso-Cel ‘Favorable’ Safety Profile in Second-line Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
February 16, 2024
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Read More
Advertisement
Dr. Coombs Spotlights Recent CHIP Updates
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse
|
February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Listen Now
Expanded Indications for Liso-Cel Under Review in US, Japan
Patrick Daly
Mantle Cell Lymphoma
|
April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Read More
FDA Requests Boxed Warning Label on CAR-T Therapies Used to Treat Blood Cancers
Leah Sherwood
Myeloma
|
February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Read More
Epcoritamab Produces Promising Responses in Patients With Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
February 20, 2024
Epcoritamab yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
Read More
Dual Treatment Shows Promising Efficacy in Untreated Follicular Lymphoma
Melissa Badamo
Indolent B-Cell Lymphoma
|
February 2, 2024
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Read More
Phase II Study: Mosunetuzumab Shows ‘Highly Encouraging Efficacy’ in Follicular Lymphoma
Melissa Badamo
Indolent B-Cell Lymphoma
|
February 14, 2024
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Read More
Liso-cel Leads to High CR Rate in Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
December 13, 2023
The abstract investigators presented data from the phase II TRANSCEND FL trial.
Read More
Outlining Phase I/II Results of Pirtobrutinib in Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
December 14, 2023
Pirtobrutinib showed potential efficacy among patients with relapsed or refractory follicular lymphoma.
Read More
Michael Dickinson, MBBS, on Bispecific Antibodies Across Lymphomas
Blood Cancer Talks
Blood Cancer Talks
|
December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Listen Now
EMA Committee Recommends Approval of Zanubrutinib for Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
October 18, 2023
The Committee for Medicinal Products for Human Use of the European Medicines Agency supported approving zanubrutinib for FL.
Read More
Proteomics Identifies Altered Protein Expression in Follicular Lymphoma
Melissa Badamo
Indolent B-Cell Lymphoma
|
October 18, 2023
The findings "may contribute to future improved risk assessment and personalized management strategies for patients."
Read More
Dr. Nastoupil on Lymphoma Highlights from the SOHO Annual Meeting
Loretta Nastoupil, MD
Meeting News
|
October 26, 2023
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
View More
Loretta Nastoupil, MD, on the Importance of Lymphoma Awareness
Loretta Nastoupil, MD
Video Insights
|
October 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Loretta Nastoupil, MD, Discusses the TRANSCEND FL Study
Loretta Nastoupil, MD
Meeting News
|
November 14, 2023
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
View More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer